Volition Announces Landmark Clinical Validation of Nu.Q® NETs Biomarker in Sepsis

Data ReadoutpositiveNu.Q® NETsPositive

AI Analysis

Summary

VolitionRx announced landmark clinical validation of its Nu.Q® NETs biomarker for sepsis, with findings published in Critical Care Medicine demonstrating high-predictive accuracy for severe sepsis outcomes. The validation supports commercial expansion across the company's $2.8 billion addressable market.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Clinical validation published in Critical Care Medicine confirming high-predictive accuracy for severe sepsis outcomes

Importance:6/10

Sentiment:

0.75

biomarker validationsepsisclinical datapublicationcommercial opportunity

Related Companies

$VNRX

Read the original article

Published by PR Newswire Biotech on August 26, 2026 12:17 PM

Read Original